To further confirm whether CD8+ T cell were essential for cabozantinib-mediated anti-tumor effects, BALB/c mice bearing Renca tumors were treated with anti-CD8-depleting antibody during cabozantinib treatment (Figures 6C, D). Here, CD8A is linked to neoplasm.